Entera Bio Ltd. Net Debt

Net Debt of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Debt growth rates and interactive chart. Net debt is the sum of all interest-bearing debt (short-term and long-term) minus cash and short-term investments. A positive number indicates the company's total debt exceeds its cash and short-term investments balances, while a negative number means the company has more cash than its total debt. This figure is also used in Enterprise value calculation.


Highlights and Quick Summary

  • Net Debt for the quarter ending June 29, 2020 was $-9.69 Million (a -26.61% decrease compared to previous quarter)
  • Year-over-year quarterly Net Debt increased by 68.92%
  • Annual Net Debt for 2019 was $-15.1 Million (a 30.74% increase from previous year)
  • Annual Net Debt for 2018 was $-11.5 Million (a 46.71% increase from previous year)
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Debt of Entera Bio Ltd.

Most recent Net Debtof ENTX including historical data for past 10 years.

Interactive Chart of Net Debt of Entera Bio Ltd.

Entera Bio Ltd. Net Debt for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-9.69 $-13.2
2019 $-15.06 $-5.73 $-7.2 $-9.34 $-15.06
2018 $-11.52 $-11.52
2017 $-7.85 $-7.85

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.